Hydroxyurea therapy requires HbF induction for clinical benefit in a sickle cell mouse model
Hydroxyurea has proven clinical efficacy in patients with sickle cell disease. Potential mechanisms for the beneficial effects include fetal hemoglobin induction and the reduction of cell adhesive properties, inflammation and hypercoagulability. Using a murine model of sickle cell disease in which f...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Ferrata Storti Foundation
2010-09-01
|
| Series: | Haematologica |
| Online Access: | https://haematologica.org/article/view/5727 |